Variant ICOS ligand immunomodulatory proteins and related compositions and methods
Provided herein are immunomodulatory proteins comprising ICOSL variants and nucleic acids encoding such proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological and oncological conditions. Compositions and methods for making and using such proteins are provided.
1. A variant ICOSL-Fc fusion protein set forth in SEQ ID NO:928.
2. A variant ICOSL-Fc fusion protein homodimer, wherein each polypeptide of the homodimer is set forth in SEQ ID NO:928.
3. A pharmaceutical composition comprising a variant ICOSL-Fc fusion protein of claim 1 , and a pharmaceutically acceptable excipient.
4. A pharmaceutical composition comprising a variant ICOSL-Fc fusion protein homodimer of claim 2 , and a pharmaceutically acceptable excipient.